Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Natural anti-inflammatory protein effective against meningitis-causing bacteria

A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).

25 May 2010

Baxa announces release of InFuse T-10 Syringe Infuser

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of the InFuse T-10 Syringe Infuser. Specifically designed for the delivery of intermittent antibiotics and other non-rate critical intravenous doses, the Baxa InFuse T-10 Syringe Infuser frees up expensive, smart infusion pumps for more critical applications and gives nurses more time to focus on patient care.

24 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

Vesicoureteral reflux more common among girls

Children with vesicoureteral reflux (VUR), in which urine flows backwards into the kidneys from the bladder, have been treated in the past with surgery or antibiotic therapy.

21 May 2010

Research and movement in future towards universal influenza virus vaccine

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

20 May 2010

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Antibiotic-resistant bacteria are becoming a growing problem around the world, and are a particular worry in hospital-acquired infections.

20 May 2010

University of Sydney hosts emerging infectious diseases and biosecurity conference

The latest research to combat emerging infectious diseases threatening Australia is being presented at the Sydney Institute of Emerging Infectious Diseases and Biosecurity Conference at the University of Sydney today.

19 May 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Four new projects, announced today, will develop biological methods that offer a new approach to antibiotic production, power generation for extremely small mechanical components, new classes of medicines and innovative techniques to study cell biology.

19 May 2010

Antibiotics have significant resistance effects on individual patients in primary care

Antibiotics prescribed in primary care make a considerable contribution to the problem of antimicrobial resistance, both in individual patients and the population as a whole, according to research from the University of Bristol published in this week’s BMJ.

18 May 2010

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.

18 May 2010

Asolva adds infection surveillance tool package to Medici system

Asolva, a leading provider of healthcare data analytics and reporting systems, has added a package of infection surveillance tools to Medici, its clinical information management system. The package will assist pharmacists, physicians and other infection preventionists in tracking and maximizing their antimicrobial stewardship programs.

18 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

A new possible treatment to treat P. aeruginosa in cystic fibrosis patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.

17 May 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Johns Hopkins Children's Center neonatologist Christoph Lehmann, M.D., has joined the nation's leading watchdog organization on health-care quality, the National Quality Forum (NQF), as a member of its newly formed Health Information Technology (HIT) advisory committee.

14 May 2010

NovaBay first-quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.

12 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

Antibiotic News and Research

Further Reading

Natural anti-inflammatory protein effective against meningitis-causing bacteria

Baxa announces release of InFuse T-10 Syringe Infuser

BinaxNOW PBP2a test to detect PBP2a in MRSA

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Vesicoureteral reflux more common among girls

Research and movement in future towards universal influenza virus vaccine

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

University of Sydney hosts emerging infectious diseases and biosecurity conference

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Antibiotics have significant resistance effects on individual patients in primary care

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

Asolva adds infection surveillance tool package to Medici system

Final data from Open-Label studies of Cinryze in patients with HAE now available

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

NovaBay first-quarter net loss increases to $1.6 million

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News